AmpC酶是临床上重要的β－内酰胺酶，编码在许多肠杆菌科和其他生物体的

AmpC enzyme is a clinically important β-lactamase, encoded on the chromosomes or plasmids of many Enterobacteriaceae and other organisms. They mediate the effects of most penicillin drugs and β-lactamase inhibitors/β-lactamases. Joint resistance to amide drugs. In many bacteria, the AmpC enzyme is inducible and can be expressed at high levels through mutations. At the same time, the AmpC enzymes encoded by chromosomes and plasmid genes are also evolving. Overexpression makes them resistant to broad-spectrum cephalosporins including cefotaxime, ceftazidime and ceftriaxone, even in certain organisms. In, mutations that reduce influx (loss of outer membrane porins) or enhance efflux (activation of efflux pump) can develop resistance to carbapenem antibiotics. In most parts of the world, although the AmpC enzyme causes less resistance than the extended-spectrum β-lactamase (ESBL), it is more difficult to detect and has a wider range. Therefore, a deeper research on AmpC is of great significance for guiding clinical testing and follow-up medication.

AmpC enzyme is clinically important β－ Lactamases, encoded on the chromosomes or plasmids of many Enterobacteriaceae and other organisms, mediate resistance to most penicillins and β－ Lactamase inhibitor/ β－ Combined resistance of lactam drugs. In many bacteria, AmpC enzyme is inducible and can be expressed at high levels by mutation. At the same time, the AmpC enzyme encoded by chromosome and plasmid genes is also evolving. Overexpression makes it resistant to a wide range of cephalosporins, including cefotaxime, ceftazidime and ceftriaxone. Even in some organisms, it is mutated by reducing influx (loss of outer membrane porin) or enhancing efflux (activation of efflux pump), It can be resistant to carbapenem antibiotics. In most parts of the world, although AmpC enzyme induced drug resistance is more broad-spectrum than production β－ Lactamase (ESBL) is less, but it is more difficult to detect and has a wider range. Therefore, further research on AmpC is of great significance for guiding clinical detection and follow-up medication.

AmpC enzyme is an important β -lactamase in clinic, which is encoded on chromosomes or plasmids of many enterobacteriaceae and other organisms. They mediate the combined resistance to most penicillin drugs and β -lactamase inhibitors/β-lactam drugs. In many bacteria, AmpC enzyme is inducible and can be expressed at a high level by mutation. At the same time, the AmpC enzyme encoded by chromosome and plasmid genes is also evolving. Over-expression makes it resistant to broad-spectrum cephalosporins including cefotaxime, ceftazidime and ceftriaxone, and even in some organisms, it can be resistant to carbapenem antibiotics by reducing the mutation of influx (loss of outer membrane pore protein) or enhancing efflux (activation of efflux pump). In most parts of the world, although AmpC enzyme causes less drug resistance than extended-spectrum β -lactamase (ESBL), it is more difficult to detect and has a wider range. Therefore, it is of great significance to conduct a deeper study on AmpC to guide clinical detection and follow-up medication.